Display options
Cite
Van Neste L, Wojno KJ, Henao R, et al. Evaluation of an RNAseq-Based Immunogenomic Liquid Biopsy Approach in Early-Stage Prostate Cancer. Cells. 2021;10(10)doi: 10.3390/cells10102567.
Van Neste, L., Wojno, K. J., Henao, R., Mane, S., Korman, H., Hafron, J., Kernen, K., Tinawi-Aljundi, R., Putzi, M., Kassis, A. I., & Kantoff, P. W. (2021). Evaluation of an RNAseq-Based Immunogenomic Liquid Biopsy Approach in Early-Stage Prostate Cancer. Cells, 10(10), . https://doi.org/10.3390/cells10102567
Van Neste, Leander, et al. "Evaluation of an RNAseq-Based Immunogenomic Liquid Biopsy Approach in Early-Stage Prostate Cancer." Cells vol. 10,10 (2021). doi: https://doi.org/10.3390/cells10102567
Van Neste L, Wojno KJ, Henao R, Mane S, Korman H, Hafron J, Kernen K, Tinawi-Aljundi R, Putzi M, Kassis AI, Kantoff PW. Evaluation of an RNAseq-Based Immunogenomic Liquid Biopsy Approach in Early-Stage Prostate Cancer. Cells. 2021 Sep 28;10(10). doi: 10.3390/cells10102567. PMID: 34685549; PMCID: PMC8533765.
Copy Download .nbib Format: NLM
Share it on

Cells. 2021 Sep 28;10(10). doi: 10.3390/cells10102567.

Evaluation of an RNAseq-Based Immunogenomic Liquid Biopsy Approach in Early-Stage Prostate Cancer.

Cells

Leander Van Neste, Kirk J Wojno, Ricardo Henao, Shrikant Mane, Howard Korman, Jason Hafron, Kenneth Kernen, Rima Tinawi-Aljundi, Mathew Putzi, Amin I Kassis, Philip W Kantoff

Affiliations

  1. Immunis.AI, Royal Oak, MI 48067, USA.
  2. Infinia ML, Duke University, Durham, NC 27708, USA.
  3. Duke University, Durham, NC 27708, USA.
  4. Yale University Center for Genomic Analysis, New Haven, CT 06511, USA.
  5. Comprehensive Urology Center, Royal Oak, MI 48073, USA.
  6. School of Medicine, Wayne State University, Detroit, MI 48201, USA.
  7. Michigan Institute of Urology, St. Clair Shores, MI 48081, USA.
  8. Urology Austin, Austin, TX 78705, USA.
  9. Harvard Medical School, Harvard University, Boston, MA 02115, USA.
  10. Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  11. Convergent Therapeutics Inc., Cambridge, MA 02138, USA.

PMID: 34685549 PMCID: PMC8533765 DOI: 10.3390/cells10102567

Abstract

The primary objective of this study is to detect biomarkers and develop models that enable the identification of clinically significant prostate cancer and to understand the biologic implications of the genes involved. Peripheral blood samples (1018 patients) were split chronologically into independent training (

Keywords: CD14+; CD2+; boosting; cancer; cells; gradient; immune; phagocytosis; transcriptomics

References

  1. Clin Cancer Res. 2011 May 15;17(10):3360-7 - PubMed
  2. PLoS One. 2012;7(3):e34392 - PubMed
  3. Microb Pathog. 2021 Aug;157:104963 - PubMed
  4. NPJ Precis Oncol. 2021 Jun 22;5(1):56 - PubMed
  5. J Leukoc Biol. 2014 Dec;96(6):969-80 - PubMed
  6. Cancer Res. 2019 Jan 1;79(1):263-273 - PubMed
  7. Curr Protoc. 2021 Mar;1(3):e90 - PubMed
  8. APMIS. 2016 Jun;124(6):433-5 - PubMed
  9. Cancer Res. 2018 Aug 1;78(15):4411-4423 - PubMed
  10. Biometrics. 1988 Sep;44(3):837-45 - PubMed
  11. N Engl J Med. 2016 Aug 4;375(5):443-53 - PubMed
  12. Blood. 2003 May 1;101(9):3509-13 - PubMed
  13. Transl Androl Urol. 2021 Jun;10(6):2809-2819 - PubMed
  14. Front Immunol. 2019 May 21;10:1111 - PubMed
  15. Blood. 2008 Aug 15;112(4):935-45 - PubMed
  16. Cancer Res. 2009 Dec 15;69(24):9202-10 - PubMed
  17. Per Med. 2019 Nov;16(6):491-499 - PubMed
  18. PLoS One. 2012;7(1):e29979 - PubMed
  19. Nat Immunol. 2002 Nov;3(11):991-8 - PubMed
  20. BMC Bioinformatics. 2013 Apr 15;14:128 - PubMed
  21. Carcinogenesis. 2014 Sep;35(9):2074-83 - PubMed
  22. Cancer Biomark. 2011-2012;11(1):1-14 - PubMed
  23. Front Immunol. 2018 Sep 11;9:2028 - PubMed
  24. Nat Commun. 2018 Jan 2;9(1):32 - PubMed
  25. Cancer Res. 2006 Apr 15;66(8):3959-62 - PubMed
  26. Lancet Oncol. 2012 Nov;13(11):1105-13 - PubMed
  27. Bioinformatics. 2014 Aug 1;30(15):2114-20 - PubMed
  28. Genome Biol. 2010;11(3):R25 - PubMed
  29. Genes Immun. 2005 Aug;6(5):388-97 - PubMed
  30. Nat Rev Immunol. 2011 Oct 25;11(11):788-98 - PubMed
  31. BMC Med. 2015 Aug 21;13:201 - PubMed
  32. Blood. 2007 Mar 1;109(5):2066-77 - PubMed
  33. Genes Dev. 2018 Sep 1;32(17-18):1105-1140 - PubMed
  34. Lab Invest. 2015 Oct;95(10):1197-206 - PubMed
  35. BMC Genomics. 2006 May 16;7:115 - PubMed
  36. Nat Methods. 2012 Mar 04;9(4):357-9 - PubMed
  37. Lancet Oncol. 2012 Nov;13(11):1114-24 - PubMed
  38. Annu Rev Immunol. 1999;17:593-623 - PubMed
  39. Blood. 1998 Aug 15;92(4):1432-41 - PubMed
  40. EBioMedicine. 2015 Jul 29;2(9):1133-44 - PubMed
  41. Int J Cancer. 2013 Jul 15;133(2):373-82 - PubMed
  42. Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7 - PubMed
  43. Nat Methods. 2013 Jan;10(1):71-3 - PubMed
  44. BMC Genomics. 2015 Apr 22;16:333 - PubMed

Publication Types